SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

Compared with DPP-4 inhibitors, SGLT-2 inhibitors were linked to a lower risk for incidental Parkinson disease among older adults with type 2 diabetes. Use of sodium-glucose cotransporter-2 (SGLT ...

There has been some research suggesting that a type of type 2 diabetes drugs called SGLT2 inhibitors could reduce the incidence of some neurodegenerative conditions including Parkinson’s disease ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

A risk for dementia was estimated to be between 2.5 percentage points lower and 0.6 percentage points greater for sodium-glucose cotransporter-2 inhibitors vs dulaglutide. The effects of sodium ...

Aims Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors are now advised as standard front line therapy for heart failure reduced ejection fraction (HFrEF) patients irrespective of whether diabetes is ...

Credit: Getty Images SGLT2 inhibitors are a class of medications commonly prescribed as a part of combination therapy for patients with type 2 diabetes. They have a wide range of potentially ...

The study investigated how sodium-glucose cotransporter-2 (SGLT2) inhibitors, known as gliflozins, affect the risk of developing neurodegenerative conditions among patients with type 2 diabetes. SGLT2 ...

Compared with DPP-4 inhibitors, SGLT-2 inhibitors were linked to a lower risk for incidental Parkinson disease among older adults with type 2 diabetes. Use of sodium-glucose cotransporter-2 (SGLT ...